期刊
FUTURE ONCOLOGY
卷 16, 期 36, 页码 3035-3043出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0595
关键词
head and neck cancer; ipilimumab; nivolumab; PD-L1; randomized controlled trial
类别
资金
- Bristol-Myers Squibb
- Inspire Medical Systems, Inc.
- APrevent Biotech GmbH
Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often requires postoperative chemoradiation with high risk of toxicity. Disease-free survival (DFS) after 2 years is approximately 70%. Combining nivolumab (N), a PD-1-inhibitor and ipilimumab (I), a CTLA4- inhibitor, may improve DFS due to antitumor effects of immunotherapy. The IMSTAR-HN study compares neoadjuvant N and N +/- I 6 months after adjuvant therapy versus standard therapy as first-line treatment for LA-HNSCC. Eligible patients have treatment-naive LA-HNSCC, Eastern cooperative oncology group performance score (PS) <= 1 and no distant metastasis. 276 patients will be randomized into two arms. Primary end point is DFS and secondary end point includes locoregional control (LRC) and overall survival (OS). This study is one of the first in HNSCCs implementing immunotherapy in first-line treatment in a curative setting. Clinical Trial Registration: NCT03700905 (ClinicalTrials.gov)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据